<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531959</url>
  </required_header>
  <id_info>
    <org_study_id>2011P002049</org_study_id>
    <secondary_id>2015-098</secondary_id>
    <secondary_id>2018P000162</secondary_id>
    <nct_id>NCT01531959</nct_id>
  </id_info>
  <brief_title>Midodrine for the Treatment of Refractory Hypotension</brief_title>
  <official_title>Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Charles Gairdner Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready&#xD;
      for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of&#xD;
      stay without increasing MGH length of stay or putting the patient at risk of being readmitted&#xD;
      to an ICU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent hypotension in critically ill patients remains a major barrier to discharging&#xD;
      patients from the intensive care unit (ICU). In our hospital, in patients with adequate&#xD;
      tissue perfusion, midodrine has been observed to treat hypotension in order to wean&#xD;
      continuous intravenous (IV) vasopressors and therefore promote ICU discharge. There are&#xD;
      several possible etiologies of hypotension in the ICU. The most frequently seen causes&#xD;
      include septic shock, hypovolemia, adrenal insufficiency, and idiosyncratic reactions from&#xD;
      medications. For patients whose reversible causes of hypotension have been addressed but&#xD;
      still require vasopressors, midodrine may prove to be a useful adjunctive medication to&#xD;
      successfully increase blood pressure. No previous studies have examined the use of midodrine&#xD;
      for the treatment of hypotension in an ICU setting. Therefore, we are investigating a new&#xD;
      indication for midodrine as the treatment of hypotension in critically ill patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Until Discontinuation of IV Vasopressors</measure>
    <time_frame>From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours</time_frame>
    <description>Measured hours from initiation of midodrine until discontinuation of IV vasopressors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>From initiation of midodrine until ICU discharge, assessed up to 45 days</time_frame>
    <description>Measured number of days from initiation of midodrine until discharge ready from the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>From initiation of midodrine until hospital discharge, assessed up to 90 days</time_frame>
    <description>Measured number of days from initiation of midodrine until discharged from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of ICU Readmission</measure>
    <time_frame>Up to 2 months after ICU discharge</time_frame>
    <description>Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias</measure>
    <time_frame>From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.</time_frame>
    <description>Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Hypotension</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Patients will be randomized to blinded to 20 mg of midodrine</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be randomized to blinded placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Admitted to the SICU&#xD;
&#xD;
          -  Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8&#xD;
             mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more&#xD;
             than 24 hours while still maintaining desired blood pressure goal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate tissue oxygenation&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Hypovolemic shock or hypotension due to adrenal insufficiency&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe organic heart disease&#xD;
&#xD;
          -  Urinary retention&#xD;
&#xD;
          -  Pheochromocytoma&#xD;
&#xD;
          -  Thyrotoxicosis&#xD;
&#xD;
          -  Midodrine as pre-admission medication&#xD;
&#xD;
          -  Any known allergies to midodrine&#xD;
&#xD;
          -  Enrollment in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Eikermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>60009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Matthias Eikermann, MD PhD</investigator_full_name>
    <investigator_title>Vice Chair of Faculty Affairs of the Department of Anesthesia Critical Care and Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>Midodrine</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>IV vasopressors</keyword>
  <keyword>ICU discharge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT01531959/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>139 participants provided informed consent and were enrolled. 3 participants subsequently did no loner meet eligibility criteria and were therefore not randomized, resulting in a total number of started/randomized participants of 136.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Midodrine</title>
          <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Patients will be randomized to blinded placebo control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Midodrine</title>
          <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Patients will be randomized to blinded placebo control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="12.6"/>
                    <measurement group_id="B2" value="66.7" spread="14.7"/>
                    <measurement group_id="B3" value="68.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APACHE II Score</title>
          <description>The Acute Physiology and Chronic Health Evaluation (APACHE II) score is an mortality prediction score used in critically ill patients. I ranges from 0 (minimum) to 71 (maximum), with lower score values representing better outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="5.2"/>
                    <measurement group_id="B2" value="14.8" spread="5.9"/>
                    <measurement group_id="B3" value="14.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SOFA Score on admission day</title>
          <description>The Sequential Organ Failure Assessment (SOFA) score is a score that allows for calculation of both the number and the severity of organ dysfunction in six organ systems (respiratory, coagulatory, liver, cardiovascular, renal, and neurologic). I ranges from 0 (minimum) to 24 (maximum), with lower score values representing better outcomes.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B2" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B3" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="8.8"/>
                    <measurement group_id="B2" value="29.8" spread="8.8"/>
                    <measurement group_id="B3" value="28.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Until Discontinuation of IV Vasopressors</title>
        <description>Measured hours from initiation of midodrine until discontinuation of IV vasopressors</description>
        <time_frame>From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Patients will be randomized to blinded placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Discontinuation of IV Vasopressors</title>
          <description>Measured hours from initiation of midodrine until discontinuation of IV vasopressors</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="10.0" upper_limit="54.0"/>
                    <measurement group_id="O2" value="22.5" lower_limit="10.4" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <description>Measured number of days from initiation of midodrine until discharge ready from the ICU</description>
        <time_frame>From initiation of midodrine until ICU discharge, assessed up to 45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Patients will be randomized to blinded placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>Measured number of days from initiation of midodrine until discharge ready from the ICU</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Measured number of days from initiation of midodrine until discharged from hospital</description>
        <time_frame>From initiation of midodrine until hospital discharge, assessed up to 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Patients will be randomized to blinded placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Measured number of days from initiation of midodrine until discharged from hospital</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="9.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="9.0" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of ICU Readmission</title>
        <description>Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor</description>
        <time_frame>Up to 2 months after ICU discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Patients will be randomized to blinded placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of ICU Readmission</title>
          <description>Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias</title>
        <description>Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).</description>
        <time_frame>From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Patients will be randomized to blinded placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias</title>
          <description>Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected daily from medical records for the period of study drug administration, an average of 59 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Midodrine</title>
          <description>Midodrine: Patients will be randomized to blinded to 20 mg of midodrine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Patients will be randomized to blinded placebo control</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial infarction/ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ventricular ectopic beats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lab parameter change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Subdural hemtoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough/dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthias Eikermann</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>6176327034</phone>
      <email>meikerma@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

